Turning Up the Heat on Heart Disease: Targeting Gamma-synuclein to Improve Cardiovascular Health


   School of Medicine, Medical Sciences & Nutrition

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
Dr J Rochford, Prof Mirela Delibegovic, Prof Graeme Nixon  No more applications being accepted  Competition Funded PhD Project (European/UK Students Only)

About the Project

Supervisors: Dr Justin Rochford, Professor Mirela Delibegovic & Professor Graeme Nixon

This PhD studentship will be undertaken within the recently established Aberdeen Cardiovascular & Diabetes Centre (https://www.abdn.ac.uk/acdc) which will provide the successful applicant with excellent training and support in all aspects of cardiovascular disease and diabetes.

Appropriately functioning adipose tissue plays an important role in cardiovascular health by safely storing lipids in the body. In obesity, adipocytes become overfilled and so are no longer able to accept excess lipids from the diet. Instead, these accumulate in other tissues such as the liver and the cardiovascular system, which can result in Type 2 diabetes and cardiovascular disease.

In previous collaborative work with investigators at the University of Cardiff, we identified gamma-synuclein as a novel regulator of adipose tissue function. Loss of gamma-synuclein reduced obesity in mice protected them from several negative consequences of consuming a high fat diet, including the accumulation of lipids in the liver. In further molecular studies, we have found that inhibiting gamma-synuclein in adipocytes increases the use of lipids as fuel in these cells and dissipation of the resultant energy via mitochondrial uncoupling. This may underlie the ability of gamma-synuclein deficient mice to reduce the inappropriate accumulation of lipids in non-adipose cells when consuming an obesogenic diet.

As part of these studies, we have also been testing potential pharmacological inhibitors of gamma-synuclein, which appear capable of mimicking genetic disruption of gamma-synuclein in adipocytes. Given the beneficial effects of inhibiting gamma-synuclein expression in vivo, these could offer a novel therapy for obesity related metabolic and cardiovascular disease.

This project will examine the effect of inhibiting gamma-synuclein genetically or pharmacologically on multiple measures of cardiovascular health. We predict that gamma-synuclein-deficient mice will be protected from lipid accumulation in the cardiovascular system, as we have previously observed in the liver, and so display reduced plaque formation in models of atherosclerosis.

To complement these in vivo studies, the project will further probe the molecular functions of gamma-synuclein in adipocytes to define how inhibiting gamma-synuclein results in these beneficial effects on metabolic health. This will include pharmacological as well as genetic manipulations using CRISPR/Cas9 mediated gene editing in cultured human adipocytes. The project will also use a range of analyses of RNA and protein expression, biochemical assays of adipocyte function and fluorescent imaging techniques.

Overall, the aim will be to uncover precisely how gamma-synuclein inhibition can improve metabolic and cardiovascular health and identify novel means by which to achieve this. This may ultimately lead to novel therapies to treat obesity-related cardiovascular disease.

You will additionally benefit from the international expertise in adipose tissue, diabetes and cardiovascular disease research within the newly formed Aberdeen Cardiovascular & Diabetes Centre. This centre at the University of Aberdeen consists of approximately thirty laboratory scientists and clinicians working collaboratively towards improving care and outcomes in patients with cardiovascular diseases and diabetes on the largest healthcare campus in Europe.

Funding Notes

This project is part of a competition funded by the Institute of Medical Sciences. The duration of the degree programme is four years (48 months) and full funding is available to UK/EU applicants only.

Candidates should have (or expect to achieve) a minimum of a 2.1 Honours degree in a relevant subject. Applicants with a minimum of a 2.2 Honours degree may be considered provided they have a Merit/Commendation/Distinction at Masters level.

Please apply for admission to the 'Degree of Doctor of Philosophy in Medical Sciences (Science)' to ensure that your application is passed to the correct school for processing.

References

(1) Mcilroy GD, Suchacki K, Roelofs AJ, Yang W, Fu Y, Bai B, Wallace RJ, De Bari C, Cawthorn WP, Han W, Delibegović M, Rochford JJ. (2018) Adipose specific disruption of seipin causes early-onset generalised lipodystrophy and altered fuel utilisation without severe metabolic disease. Mol Metab. Epub ahead of print. PMID:9459250.

(2) Thompson D, Morrice N, Grant L, Le Sommer S, Ziegler K, Whitfield P, Mody N, Wilson HM, Delibegović M. (2017) Myeloid protein tyrosine phosphatase 1B (PTP1B) deficiency protects against atherosclerotic plaque formation in the ApoE-/- mouse model of atherosclerosis with alterations in IL10/AMPKα pathway. Mol Metab. 6(8):845-853. PMID:28752048.

(3) Millership S, Ninkina N, Guschina IA, Norton J, Brambilla R, Oort PJ, Adams SH, Dennis RJ, Voshol PJ, Rochford JJ, Buchman VL. (2012) Increased lipolysis and altered lipid homeostasis protect γ-synuclein-null mutant mice from diet-induced obesity. Proc Natl Acad Sci U S A. 109(51):20943-8. PMID:23213245.